Cytokinetics Stock News

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2022 it granted stock options to purchase an aggregate of

Aficamten Reduced LVOT Gradients in Patients on DisopyramideWith No Instances of Left Ventricular Ejection Fraction Below 50%

Cytokinetics (CYTK) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean

Cytokinetics (CYTK) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean

Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach

The heavy selling pressure might have exhausted for Cytokinetics (CYTK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analys

The heavy selling pressure might have exhausted for Cytokinetics (CYTK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analys

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2021 it granted stock options to purchase an aggregate o

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ: CYTK ) today announced that on December 31, 2021 it granted stock options to purchase an aggregate of 90,000 shares of common stock to 9 new employees, whose employment commenced in December 2021, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $45.58 per share, which is equal to the closing price of the Company''s common stock on December 31, 2021, and will vest over 4 years, with 1/4 th of the shares underlying the employee''s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48 th of the shares underlying each employee''s option over the subsequent 36 months, subject to the new employee''s continued service with the Company. Each stock option has a 10-year term and is subject to the terms and conditions of the Company''s Amended and Restated 2004 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

Commodities were the only major index to gain ground last week. Read here for a detailed review...

Cytokinetics Inc (CYTK) shares closed this week 22.9% lower than it did at the end of last week. The stock is currently down 22.9% year-to-date, up 63.3% over the past 12 months, and up 170.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $46.95 and as low as $34.00 this week.Shares closed 26.6% below its 52-week high and 98.4% above its 52-week low.Trading volume this week was 16.1% higher than the 10-day average and 38.4% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 657.9% The company's stock price performance over the past 12 months beats the peer average by -283.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Cytokinetics establishes partnership deal with Royalty Pharma for omecamtiv mecarbil and aficamten. Up to $450 million in total is expected for this particular deal. NDA Filing of omecamtiv mecarbil f

Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to p

Cytokinetics Inc (CYTK) shares closed 0.9% higher than its previous 52 week high, giving the company a market cap of $3B. The stock is currently up 114.9% year-to-date, up 113.3% over the past 12 months, and up 260.2% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 32.6% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -566.7% The company's stock price performance over the past 12 months beats the peer average by -514.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.